ANI Pharmaceuticals/$ANIP

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About ANI Pharmaceuticals

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Ticker

$ANIP
Sector
Health
Primary listing
NASDAQ

Employees

897
Headquarters
Baudette, United States
Website
www.anipharmaceuticals.com

ANIP Metrics

BasicAdvanced
$2B
-
-$0.65
0.58
-

What the Analysts think about ANIP

Analyst ratings (Buy, Hold, Sell) for ANI Pharmaceuticals stock.

Bulls say / Bears say

ANI posted Q2 2025 net revenues of $211.4 million, up 53.1% year-over-year, leading management to increase full-year 2025 revenue guidance to a range of $818 million to $843 million, reflecting strong growth across its Rare Disease and Generics divisions.
Purified Cortrophin® Gel achieved net revenues of $81.6 million in Q2 2025, a 66.0% year-over-year jump, driven by a record number of new patient starts, signaling strong demand for ANI’s leading rare disease treatment.
ANI paid $17.25 million to buy out its 3.125% perpetual royalty commitment to SWK Funding LLC on ILUVIEN and YUTIQ, ending future royalty payments as of January 1, 2025 and improving profitability for its retina product line.
U.S. tariffs on pharmaceutical imports may force generics companies like ANI to bear higher input costs, which could squeeze margins for its Generics segment due to typically tight pricing.
Growth for ILUVIEN and YUTIQ in the first quarter was limited by challenges with Medicare market access and turnover in the ophthalmology salesforce, highlighting ongoing difficulties for these important rare disease products.
With Rare Disease segment revenues projected to make up about 50% of total 2025 revenue, ANI is heavily dependent on a small number of products—mainly Cortrophin Gel and retina implants—creating a concentration risk should clinical or competitive problems arise.
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.

ANIP Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ANIP Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ANIP

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs